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(mcm5s2U)Familial dysautonomia (FD) is a recessive neurodegenerative genetic disease. FD is caused by a mutation
in the IKBKAP gene resulting in a splicing defect and reduced levels of full length IKAP protein. IKAP
homologues can be found in all eukaryotes and are part of a conserved six subunit protein complex, Elon-
gator complex. Inactivation of any Elongator subunit gene in multicellular organisms cause a wide range
of phenotypes, suggesting that Elongator has a pivotal role in several cellular processes. In yeast, there is
convincing evidence that the main role of Elongator complex is in formation of modiﬁed wobble uridine
nucleosides in tRNA and that their absence will inﬂuence translational efﬁciency. To date, no study has
explored the possibility that FD patients display defects in formation of modiﬁed wobble uridine nucleo-
sides as a consequence of reduced IKAP levels. In this study, we show that brain tissue and ﬁbroblast cell
lines from FD patients have reduced levels of the wobble uridine nucleoside 5-methoxycarbonylmethyl-
2-thiouridine (mcm5s2U). Our ﬁndings indicate that FD could be caused by inefﬁcient translation due to
lower levels of wobble uridine nucleosides.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Familial dysautonomia (FD), initially called Riley-Day syndrome
is a neurodegenerative autosomal recessive genetic disorder pri-
marily found amongst the Ashkenazi Jewish population [1,2]. FD
patients display a variety of clinical features such as cardiovascular
dysfunction, decreased pain and temperature sensation, blood
pressure variability, vomiting crises, lack of overﬂow tears and
increased sweating [3,4]. Nearly all FD patients have a mutation
in the donor splice site of intron 20 of the IKBKAP gene which leads
to aberrant splicing. The missplicing results in skipping of exon 20
in a tissue speciﬁc manner and consequently reduced levels of the
full length IKAP protein [5–8].
The IKAP protein homologue Elp1p has been extensively stud-
ied in the yeast Saccharomyces cerevisiae. The Elp1p is part of a
six subunit protein complex Elp1p–Elp6p and this complex was
initially described as a histone acetyltransferase (HAT) that
associates with the hyperphosphorylated elongating form of RNApolymerase II (Pol II) [9]. Therefore the complex was named Elon-
gator complex [9–12]. The HAT activity of Elongator complex
reside in the Elp3p subunit since in vitro this subunit transfer
acetyl groups from acetyl-CoA to histones [13,14]. Consistent with
a role in transcription, null mutants of genes encoding Elongator
subunits results in defects in Pol II transcription [9,10,13–15]. In
addition to defects in Pol II transcription, deletions of genes encod-
ing Elongator subunits in yeast show multiple phenotypes includ-
ing defects in DNA repair, telomeric gene silencing, exocytosis and
formation of the 5-carbamoylmethyluridine (ncm5U), 5-meth-
oxycarbonylmethyluridine (mcm5U) and 5-methoxycarbonyl-
methyl-2-thiouridine (mcm5s2U) nucleosides at wobble position
in tRNAs [16–18]. It was controversial whether Elongator complex
is involved in multiple cellular processes or if it participate in one
key process inﬂuencing multiple downstream cellular processes. In
yeast, there is convincing evidence that the primary role of Elonga-
tor complex is in formation of the ncm5 and mcm5 side chains on
wobble uridines in tRNA [18,19]. In Elongator mutants, overex-
pression of various combinations of tRNALyss2UUU, tRNA
Gln
s2UUG and
tRNAGlus2UUC which in wild type have the mcm
5s2U nucleoside
restored all defects mentioned above but not the defect in
formation of the ncm5U, mcm5U and mcm5s2U nucleosides
[19,20]. Presence of ncm5U, mcm5U and mcm5s2U nucleosides
are important for proper decoding of A- and G-ending codons in
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tRNAGlns2UUG and tRNA
Glu
s2UUC most likely compensate for inefﬁcient
codon/anticodon interaction during translation due to the absence
of modiﬁcations at wobble position. Likely translational targets are
mRNAs enriched in these codons or having these codons in a
certain context. This was recently veriﬁed for the cdr2+ gene of
Schizosaccharomyces pombe where changes of the Elongator tRNA
modiﬁcation dependent AAA lysine codons to Elongator indepen-
dent AAG lysine codons signiﬁcantly improved expression of the
protein encoded by the modiﬁed cdr2+ gene [23].
Elongator complex is conserved in multicellular eukaryotes and
six subunit protein complexes have been puriﬁed from humans
and plants [12,25–27]. Mutations in the ELP1/IKBKAP gene homo-
logues of the plant Arabidopsis thaliana, the worm Caenorhabditis
elegans and mouse Mus musculus causes defects in formation of
wobble uridine modiﬁcations [28–30]. As in yeast, depletion of
Elongator subunits in multicellular organisms show pleiotropic
phenotypes implicating a role in very many cellular processes
[29–39]. Phenotypes observed in ﬁbroblasts derived from FD
patients are reduced histone H3 acetylation and reduced Pol II
transcription of several genes encoding proteins required for
proper cell motility [25,31]. However, in FD ﬁbroblasts it is
unknown if reduced histone H3 acetylation could be a conse-
quence of reduced amounts of the mcm5s2U nucleoside at wobble
position in tRNA.
In yeast, the Elongator complex is required for formation of the
ﬁrst intermediate, likely to be 5-carboxymethyluridine (cm5U), in
formation of the ncm5U, mcm5U and mcm5s2U nucleosides at wob-
ble position in tRNA [40–44]. In essentially all archaea, homo-
logues to the Elp3 protein are found but not the other subunits
of the Elongator complex [45,46]. Recently, the archaea Methano-
caldococcus infernus Elp3 protein produced in Escherichia coli was
shown to catalyse the formation of cm5U by transfer of an acetyl
radical originating from acetyl-CoA in the presence of S-adenosyl-
methionine (SAM) [46]. Thus, this reaction utilizes both the HAT
and Radical SAM domains found in Elp3p. In mammals, a fraction
of the Elongator complex dependent mcm5U wobble nucleoside
is further converted into the diastereomeric modiﬁcations (R)-
and (S)-5-methoxycarbonylhydroxymethyluridine (mchm5U)
[47,48] whereas in plants and worms the (S)-mchm5U nucleoside
is found [48–50].
In this study, we analyzed the levels of the mcm5s2U nucleoside
in brain tissue and ﬁbroblast cell lines derived from healthy indi-
viduals and FD patients. Our results show that FD patients have
reduced levels of the mcm5s2U nucleoside in tRNA.
2. Materials and methods
2.1. Tissue specimens, cell lines and media
Tissue samples were from the parietal- or frontal-cortex of cere-
brum from patients with UMB#: M3697M (FD), M3783M (FD),
1670 (non-FD), 880 (non-FD), 1744 (non-FD) and 5120 (non-FD)
were from NICHD Brain and tissue bank for developmental disor-
ders. Fibroblasts GM03348 (non-FD), GM04959 (FD), AG08498
(non-FD) and GM04899 (FD) were from Coriell Cell Repositories.
Fibroblasts were grown in DMEM Glutamax-I media (Gibco) with
15% FBS (Sigma-Aldrich), sodium pyruvate (Gibco), MEM non-
essential amino acids (Gibco) and Penicillin-Streptomycin (Gibco)
or Antibiotic-Antimycotic (Gibco) at 37 C in a humidiﬁed
atmosphere with 5% CO2.
2.2. tRNA isolation and analysis by HPLC
Approximately 1 g of tissue from the parietal- or frontal-cortex
of cerebrum was cut into small pieces. The tissue washomogenized by grinding in the presence of liquid nitrogen. The
homogenized tissue was dissolved in 7 mL TRIzol (Life Technolo-
gies) and samples were vortexed for 20 min at room temperature
(RT). Samples were centrifuged for 20 min at 12,000g and the
supernatant was mixed with an equal volume of chloroform and
vortexed 5 min at RT. Samples were subjected to centrifugation
at 12,000g for 20 min and the aqueous phase was mixed with
5 mL of water saturated phenol and 0.5 mL of chloroform. Samples
were vortexed for 5 min at RT and centrifuged for 20 min at
12,000g. Total RNA was precipitated with 0.7 volumes of isopropa-
nol, centrifuged at 12,000g for 20 min and separated from high
molecular weight RNA as earlier described [20]. Fibroblasts were
collected at 90–95% conﬂuency from at least 14 culture ﬂasks with
the bottom area of 75 cm2. Fibroblasts were detached using
Trypsin and collected by centrifugation at 390g for 5 min. Total
tRNA was prepared as earlier described [20] using PBS instead of
0.9% NaCl to resuspend harvested cells. tRNA was digested to
nucleosides using nuclease P1 (Sigma–Aldrich) and bacterial
alkaline phosphatase (Sigma–Aldrich) and analyzed as earlier
described [51].2.3. Western blot
Fibroblasts were grown to 80–95% conﬂuency. Cells were
scraped off in the presence of RIPA buffer (150 mM sodium chlo-
ride, 1.0% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS,
50 mM Tris pH 8.0) supplemented with cOmplete Protease Inhibi-
tor Cocktail Tablet (Roche). Cells were agitated for 30 min at 4 C
and centrifuged for 20 min at 12000 rpm at 4 C. Proteins in the
supernatant were separated on 7.5% SDS–PAGE and transferred
to an Amersham™ Hybond ECL membrane (GE Healthcare). Mem-
branes were incubated with antibodies in 5% non-fat dried milk in
PBS. IKAP was detected using a monoclonal Anti-IKBKAP antibody
(Sigma–Aldrich, 0.5 mg/ml, mouse, 1:200) and actin by anti-beta
Actin antibody (Abcam, 1 mg/ml, mouse, 1:4000). Secondary anti-
body was a horseradish peroxidase-conjugated anti-mouse IgG
antibody (GE Healthcare, 1:4000). Signals were detected using
Amersham ECL Western blotting detection reagents (GE
Healthcare). Signals were quantiﬁed using the ImageJ software.3. Results and discussion
To investigate if FD patients show lower levels of the mcm5s2U
nucleoside in tRNA we analyzed levels of this nucleoside in tissue
derived from the parietal- and frontal-cortex of cerebrum of two
FD patients and six non-FD individuals. Total tRNA was analysed
by high-performance liquid chromatography (HPLC). Quantiﬁca-
tion of the mcm5s2U nucleoside levels revealed that tRNA
extracted from FD brain tissue has 65–71% of the mcm5s2U nucle-
oside levels observed in tRNA from the non-FD brain tissue. (Fig. 1
and Table 1). Since we only had access to brain tissue from two
deceased FD patients we decided to continue our work with ﬁbro-
blast cells obtained from FD patients and non-FD individuals. To
conﬁrm that our FD ﬁbroblasts had a reduction of the IKAP-protein
we performed a Western blot using an IKAP-speciﬁc antibody
(Fig. 2). The Western blot show a distinct reduction in levels of
IKAP in the FD derived ﬁbroblasts compared to ﬁbroblasts derived
from non-FD individuals. HPLC analysis of the mcm5s2U nucleoside
in total tRNA extracted from non-FD and FD ﬁbroblasts revealed
that FD ﬁbroblasts have 64% of the mcm5s2U nucleoside levels
observed in the non-FD ﬁbroblasts (Fig. 3 and Table 1). We also
tried to analyze levels of the modiﬁed nucleoside ncm5U which
is dependent on Elongator complex for its formation [18,28–30].
However, the amount of ncm5U could not be quantiﬁed by HPLC
analysis due to co-migration with an unrelated peak (data not
Fig. 1. Brain tissue from familial dysautonomia (FD) patients show reduced levels of the mcm5s2U modiﬁed wobble nucleoside. HPLC analysis of modiﬁed tRNA nucleosides
from parietal cortex. (A) Non-FD individual (1670). (B) FD patient (3697). HPLC analysis of modiﬁed tRNA nucleosides from the frontal cortex. (C) Non-FD individual (1744).
(D) FD patient (3783). The part of the chromatogram between the retention times 46.5 and 53 min (A and B) and 44.5 and 51 min (C and D) are shown. Chromatograms are
monitored at 254 nm. Abbreviations: (m22G) N2,N2-dimethylguanosine; (mcm5s2U) 5-methoxycarbonylmethyl-2-thiouridine, (t6A) N6-threonylcarbamoyladenosine. Asterisk
(⁄) indicates an unknown peak.
Table 1
Content of modiﬁed nucleosides in total tRNA isolated from brain tissue and ﬁbroblast cell lines from familial dysautonomia (FD) patients and non-FD individuals.
Samples W Cm m1G m2G m22G mcm5s2U % of Non-FD
Parietal Cortex Non-FD 1670 1.00 1.00 1.00 1.00 1.00 1.00 65%
FD 3697 1.00 0.95 1.11 1.11 1.09 0.65
Frontal Cortex Non-FD 880 1.00 1.00 1.00 1.00 1.00 1.00 71%
1744 1.00 1.12 0.96 0.98 0.99 1.00
5120 1.00 1.09 0.97 1.00 0.99 0.88
FD 3783 1.00 1.05 0.99 0.99 1.02 0.68
Fibroblast Non-FD GM03348 1.00 1.00 1.00 1.00 1.00 1.00 64%
AG08498 1.00 1.07 0.97 0.90 1.06 0.90
FD GM04899 1.00 0.97 1.08 1.01 1.04 0.67
GM04959 1.00 1.06 1.03 0.87 1.06 0.54
Pseudouridine (w) was used as an internal standard. The numbers are ratios of various modiﬁed nucleosides (modiﬁed nucleoside/w) in total tRNA isolated from ﬁbroblasts or
brain tissue (parietal cortex and frontal cortex). In each set, levels of modiﬁed nucleosides from GM03348, 1670 and 880 were set to 1. Values for mcm5s2U are shown in bold.
Percentage of mcm5s2U in FD relative to non-FD samples (% of non-FD) is calculated by the average value for FD derived samples divided by the average value from the non-
FD samples in each set (Fibroblasts, Parietal cortex and Frontal cortex).
Abbreviations: (w) pseudouridine; (Cm) 20-O-methylcytidine; (m1G) 1-methylguanosine; (m2G) N2-methylguanosine; (m22G) N2,N2-dimethylguanosine; (mcm5s2U)
5-methoxycarbonylmethyl-2-thiouridine.
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Fig. 2. Fibroblasts from familial dysautonomia (FD) patients display reduced levels
of the IKAP protein. Protein was extracted from ﬁbroblasts derived from non-FD
individuals (GM03348, AG08498) and FD patients (GM04899, GM04959). Levels of
IKBKAP were determined by Western blot analysis with an IKBKAP speciﬁc
antibody. Actin levels were used as loading control. Ratio IKAP/actin was set to
1.00 in GM03348 (non-FD) and other samples were normalized to GM03348.
Fig. 3. Fibroblasts derived from familial dysautonomia (FD) patients show reduced
levels of the mcm5s2U modiﬁed wobble nucleoside. HPLC analysis of modiﬁed tRNA
nucleosides from ﬁbroblast cell lines. (A) Non-FD individual (GM03348). (B) FD
patient (GM04899). The part of the chromatogram between the retention times
48.8 and 54 min are shown. Chromatograms are monitored at 254 nm. Abbrevia-
tions: (m22G) N2,N2-dimethylguanosine; (mcm5s2U) 5-methoxycarbonylmethyl-2-
thiouridine, (t6A) N6-threonylcarbamoyladenosine. Asterisk (⁄) indicates an
unknown peak.
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speciﬁc we compared levels of other modiﬁed nucleosides in total
tRNA isolated from FD patients and non-FD individuals. We found
that of the nucleosides analysed, only mcm5s2U was reduced in FD
brain tissue as well as FD ﬁbroblasts (Table 1). The reduction in
mcm5s2U levels we observed is similar to the reduction of
mcm5s2U observed in studies of yeast kti13 null mutants [52].
Strikingly, kti13 null mutants display similar but weaker pheno-
types than Elongator null mutants [19,53]. These results suggest
that partial loss of the modiﬁed wobble nucleosides in tRNA is
sufﬁcient to reduce translational efﬁciency causing multiple
phenotypes. Furthermore, a study in C. elegans where the IKBKAP
homologue ELPC-1 was inactivated cause defects in translation
[29]. In addition, the same study observed that ELPC-1::GFP report-
ers are strongly expressed in a subset of chemosensory neurons
required for salt chemotaxis learning. Inactivation of the elpc-1
gene causes a defect in salt chemotaxis learning, associated with
posttranscriptional reduction of neuropeptide and decreased
accumulation of acetylcholine in the synaptic cleft [29]. Thus in
C. elegans a functional ELPC-1 is relevant for proper neurological
function. Similarly, inefﬁcient translation in nervous tissues of FD
patients due to partial loss of the mcm5s2U nucleoside in tRNA
may be the cause for the neurodegenerative nature of the disease.
In conclusion, we demonstrate that brain tissue and ﬁbroblasts
from FD patients show reduced levels of the mcm5s2U nucleoside
at wobble position in tRNA. We found that brain tissue from FD
patients has 65–71% of the mcm5s2U nucleoside levels observed
in tRNA from non-FD brain tissue. Furthermore, ﬁbroblasts from
FD patients have 64% of the mcm5s2U nucleoside levels observed
in the non-FD ﬁbroblasts. These results suggest that lower levels
of the IKAP protein due to aberrant splicing of IKBKAP cause
reduced amounts of the mcm5s2U nucleoside in tRNA. A complete
loss of modiﬁed wobble uridine nucleosides in FD patients was not
expected as mice homozygous ikbkap/ knockouts are embryonic
lethal [54]. Our results show that IKAP is required for formation of
the mcm5s2U nucleoside at wobble position in tRNA implicating
that FD may be the result of inefﬁcient translation.
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